SVB Securities analyst Daina Graybosch maintained a Buy rating on Affimed (AFMD - Research Report) on August 11. The company's shares closed yesterday at $3.32.Graybosch covers the Healthcare sector, focusing on stocks such as 2seventy bio, Compugen, and Merck & Company. According to TipRanks, Graybosch has an average return of -14.2% and a 38.31% success rate on recommended stocks. Affimed has an analyst consensus of Strong Buy, with a price target consensus of $9.50, implying a 186.14% upside from current levels. In a report released on August 12, Berenberg Bank also reiterated a Buy rating on the stock with a $10.00 price target.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-their-buy-rating-for-affimed-afmd?utm_source=advfn.com&utm_medium=referral